After a phase I trial that showed a remarkable clinical activity in heavily pretreated patients with HER2-positive and HER2-low BC and led to a FDA fast track designation, SYD985 compared favorably with standard of care in the phase III TULIP trial. The gene discussed is ERBB2; the disease is breast cancer.